MedTrace Logo

A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic Conjunctivitis

NCT05314621 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2022-09-02

No results posted yet for this study

Summary

This is a single-center, randomized, double-masked, parallel study.

Conditions

  • Allergic Conjunctivitis

Interventions

DRUG

olopatadine hydrochloride ophthalmic solution 0.7%)

Pataday® Once Daily Relief Extra Strength (eyedrop)

DRUG

Fluticasone Propionate

Flonase® Allergy Relief (nasal spray)

DRUG

Tears Naturale

Tears Naturale® II (eye drop)

DRUG

Saline nasal spray

Saline nasal spray (nasal spray)

Sponsors & Collaborators

  • Andover Research Eye Institute

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-31
Primary Completion
2022-07-24
Completion
2022-07-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05314621 on ClinicalTrials.gov